OS of patients by initial t-MN–directed therapy
| Initial therapy . | No. patients (%) . | 1-y OS % (95% CI) . | 5-y OS % (95% CI) . |
|---|---|---|---|
| Intensive induction | 38 (45%) | 67 (53-84) | 27 (16-47) |
| HMA | 24 (29%) | 52 (38-78) | 21 (9-50) |
| Other therapy | 5 (6%) | 40 (14-100) | 20 (3-100) |
| Best supportive care | 17 (20%) | 29 (14-61) | 18 (6-49) |
| All therapies | 84 | 54 (44-66) | 24 (16-35) |
| Initial therapy . | No. patients (%) . | 1-y OS % (95% CI) . | 5-y OS % (95% CI) . |
|---|---|---|---|
| Intensive induction | 38 (45%) | 67 (53-84) | 27 (16-47) |
| HMA | 24 (29%) | 52 (38-78) | 21 (9-50) |
| Other therapy | 5 (6%) | 40 (14-100) | 20 (3-100) |
| Best supportive care | 17 (20%) | 29 (14-61) | 18 (6-49) |
| All therapies | 84 | 54 (44-66) | 24 (16-35) |
HMA, hypomethylating agent.